Keyword: Turnstone Biologics
Fierce 15 winner Turnstone Biologics has penned a near $1 billion biobucks deal with biotech’s best friend, Takeda.
Human Longevity CFO/COO departs after scandal; Sangamo loses another top executive; McCann Health fires chief creative for conduct violation and more.
Pfizer creates COO role, Bayer replaces consumer health chief, Turnstone poaches Bristol-Myers executive as new R&D head and more.
Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D.
The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once data from two ongoing phase 1/2 trials are available.
Turnstone Biologics is hoping to buck a difficult trend in the research world of oncolytic viruses and cancer vaccines by using a combined and systemic approach to create a truly next-generation therapy in immuno-oncology.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.
Turnstone Biologics will use its new cash pot to both boost and expand its pipeline of oncolytic viral immunotherapies with help from new investors OrbiMed and F-Prime Capital Partners.